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Abstract
Between 2011 and 2013 the number of recorded malaria cases had more than
doubled, and between 2009 and 2013 had increased almost 4-fold in
MSF-OCA (Médecins sans Frontières – Operational Centre Amsterdam)
programmes in the Democratic Republic of the Congo (DRC). The reasons for
this rise are unclear. Incorrect intake of Artemisinin Combination Therapy (ACT)
could result in failure to treat the infection and potential recurrence. An
adherence study was carried out to assess whether patients were completing
the full course of ACT.
One hundred and eight malaria patients in Shamwana, Katanga province, DRC
were visited in their households the day after ACT was supposed to be
completed. They were asked a series of questions about ACT administration
and the blister pack was observed (if available).
Sixty seven (62.0%) patients were considered probably adherent. This did not
take into account the patients that vomited or spat their pills or took them at the
incorrect time of day, in which case adherence dropped to 46 (42.6%). The
most common reason that patients gave for incomplete/incorrect intake was
that they were vomiting or felt unwell (10 patients (24.4%), although the
reasons were not recorded for 22 (53.7%) patients). This indicates that there
may be poor understanding of the importance of completing the treatment or
that the side effects of ACT were significant enough to over-ride the pharmacy
instructions.
Adherence to ACT was poor in this setting. Health education messages
emphasising the need to complete ACT even if patients vomit doses, feel
unwell or their health conditions improve should be promoted.
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Introduction
Despite a wealth of natural resources, the Democratic Republic of 
the Congo (DRC) has one of the lowest per capita incomes in the 
world1 and in 2014 ranked 186th (out of 187 countries) in the United 
Nations Development Programme’s human development index2.
Médecins Sans Frontières-Operational Centre Amsterdam (MSF-
OCA) has been working in the provinces of North Kivu and South 
Kivu since the early 1990s and in Katanga since 2003. MSF-OCA 
operates health programmes in Mweso and Walikale in North Kivu; 
Baraka and Kimbi Lulimba in South Kivu; and Shamwana, Katanga 
(DRC).
Between 2011 and 2013, the number of recorded malaria cases 
more than doubled and between 2009 and 2013, increased almost 
4-fold in MSF-OCA programmes in DRC (Figure 1a). The number 
of projects that MSF-OCA supported between 2009 and 2013 has 
however varied during that time. Hence, restricting the analysis to 
the fixed programmes only (in Baraka (South Kivu), Shamwana 
(Katanga) and Mweso (North Kivu)), the general trend still appears 
to be a marked increase in malaria cases (Figure 1b).
In Katanga the general trend is less clear for malaria cases. How-
ever this is likely due to the variable numbers of projects supported 
between 2009 and 2013 (Figure 2a). Focussing on the fixed project 
in Shamwana, there has been a marked increase in malaria cases 
(Figure 2b).
In 2013 MSF clinic staff in Shamwana began to identify patients 
returning to the clinic with complicated severe malaria after hav-
ing already been prescribed the anti-malarial treatment. It was not 
known if these were treatment failures or re-infections.
This was an alarming increase in malaria incidence which cannot be 
explained by displacement of non-immune populations from non-
endemic regions (mountains) to endemic malaria regions as the 
populations have been relatively stable since 2008.
The World Health Organisation (WHO)-recommended strategies 
for malaria control fall into two major areas: prevention and case 
management3. These strategies work against both the transmission 
of the parasite from mosquito vector to humans (and from humans 
to mosquitoes) and the development of illness and severe disease 
Figure 1. Confirmed malaria cases in MSF-OCA programmes and in fixed programmes in Baraka, Shamwana and Mweso in 2009–2011.
Figure 2. Confirmed malaria cases in Katanga and in Shamwana, Katanga in 2009–2011.
a b
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      Amendments from Version 1
Due to an error in Production the supplementary data section 
was accidentally omitted from the first version of this article. 
F1000Research takes responsibility for this error and the data is 
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See referee reports
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Table 1. Final classification scheme of patients, according to the treatment intake and the presence of the 
medication blister packaging.
Intake Blister packaging Final classification
Incomplete Present Certain non-adherence (pills remaining)
Incomplete Not present Probable non-adherence (patient describes incomplete number of pills taken)
Incorrect Present or not Probable non-adherence (patient describes incorrect time schedule or dosage)
Correct Present or not Probable adherence (patient describes correct number of pills taken, time schedule and dosage)
in humans3. The former is achieved in Shamwana through the 
distribution of long-lasting insecticide-treated bednet (LLIN) in a 
targeted manner (pregnant women and under 5 year old malaria 
patients) and the latter through Artemisinin Combination Therapy 
(ACT) of confirmed malaria cases (the national protocol of DRC is 
Artesunate and Amodiaquine (ASAQ) administered in a fixed dose 
combination (FDC) as a first-line ACT). These strategies do not 
seem to be having an impact on malaria incidence in MSF settings 
in DRC.
The current study explored whether this increase in cases could be 
explained by patients failing to complete the full three day course 
and adhering to the time schedule and dosage prescribed for ASAQ. 
Poor adherence increases drug pressure and thus the risk of devel-
oping resistance. Moreover, incorrect or incomplete intake could 
result in failure to treat the infection and potential recurrence.
Materials and methods
Study design
The study was conducted in Shamwana, Katanga, DRC. Katanga 
has an average temperature of 24°C and two seasons, rainy between 
November and March and dry from April to October. MSF-OCA 
has been working in the province of Katanga since 2003. MSF-OCA 
supports Shamwana hospital to provide free secondary health care 
and supports more than four health centres. The MSF catchment 
population included Shamwana town and the nearby village of 
Nsangwa.
Sample size
For previous ACT adherence assessments, adherence was always 
approximately 60%4–9. The sample size was therefore based on the 
conservative estimated adherence of 50% (in order to obtain the 
maximum sample size). With a precision of 10% and an α-error of 
5%, n=97 patients were required. Assuming a proportion of patients 
lost to follow-up or withdrawn of 20%, the total sample size needed 
for the home visits was thus n=117 patients. Similarly, a sample 
size of 117 was calculated for the exit interviews.
To prevent bias due to a change in prescribing and educating behav-
iour by health staff, the health staff were informed that a study 
would start but the exact purpose of the study (measuring patient 
adherence) was at no time revealed to them. The explanation was 
that this was a mapping exercise of where patients attending the 
health centre were mainly coming from.
Study procedure and questionnaires
Centre questionnaire
At the health centre level, all patients were interviewed using a 
short “centre”-questionnaire. This included the patient’s name, age, 
sex, the number and type of prescriptions, and the patient’s address 
in sufficient detail.
Home questionnaire
Study patients for the “home”-questionnaire were selected through 
systematic sampling of eligible patients (aged more than 1 year with 
a positive malaria rapid diagnostic test (RDT) result that had been 
prescribed ASAQ) from the “centre”-questionnaires. Study patients 
were visited at home on Day 3 (the health centre visit was on Day 0) 
and interviewed using the “home” questionnaire to assess patient 
adherence. Socio-demographic questions about the household were 
followed by a systematic account of how the pills were taken. A 
correct treatment schedule instrument was used to guide the ques-
tions on adherence. Lastly, some questions about knowledge of 
malaria cause and prevention were asked. Any sick patients were 
referred to the health centre.
Exit questionnaire
After all ‘home’-questionnaires were completed, exit interviews 
were carried out at the health centre using the “exit”-questionnaire 
to provide further information on patient/caretaker understanding 
of ACT and pharmacy dispensing practices.
Adherence definitions
A dose was considered correctly taken if according to the patient or 
caretaker’s verbal account the prescribed amount of pills was taken 
and it was neither spat out nor vomited.
There are no standard definitions for adherence so the following 
were used (Table 1).
Certain incomplete intake or certain non-adherence: Any patient 
that showed blister packaging still containing any ASAQ pills was 
certain to have taken an incomplete treatment. There was absolute 
certainty that the treatment schedule was not completed.
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Probable incomplete intake or probable non-adherence:  Accord-
ing to the patient/caretaker’s account, all pills were not taken so this 
patient was probably non-adherent. The blister packaging presented 
was empty or could not be shown.
Probable incorrect intake or probable non-adherence: If 
according to the patient/caretaker’s account ASAQ was not taken 
following the prescribed time schedule or dosage, it was assumed 
the patient took the complete treatment but in an incorrect way. The 
blister packaging presented was empty or could not be shown.
Probable correct intake or probable adherence: Only those 
patients who stated they had taken the complete treatment schedule, 
following the treatment protocol exactly were considered “probably 
adherent” (this was not ‘certain’ as each dose had not been observed). 
The blister packaging presented was empty or could not be shown.
Data management and analysis
Data for each subject were entered into EpiData 3.1 software10. Data 
were summarised by number and percentages for categorical vari-
ables. Continuous variables were summarised using means, medi-
ans and ranges. Adherence status was calculated and expressed as 
a percentage. Confidence intervals were calculated using binomial 
and multinomial formulae. To calculate the associations between 
risk factors and adherence status logistic regressions was used and 
the results expressed as odds ratios and 95% confidence intervals. 
Data analysis was conducted using Stata 13.011.
Results
Survey profile
In total, 274 people completed the ‘centre’ questionnaires. Among 
those, 150 (54.7%) were diagnosed with malaria and given a pre-
scription for ACT. Of these malaria patients 17 were aged <1 year 
so were excluded. Onehundred and seventeen (42.7%) of the 133 
(48.5%) patients that satisfied the inclusion criteria were selected 
for home visits as these were the maximum that could be achieved 
during daily visits. However, only 108 (39.4%) of these eligible 
patients completed home questionnaires. The remaining 9 (3.3%) 
patients were considered lost to follow-up (Table 2). A total of 117 
exit questionnaires were completed for patients who had received 
an ACT prescription in one day (Table 2). Nobody refused to par-
ticipate in the study.
Socio-demographic description
The mean age of the patients was 10.5 years and ranged from 1 
to 57 years (median 5 years, Q25–Q75: 2–12.5, Table 3). Sixty 
(55.6%) patients were aged ≤5 years. The sex ratio was 0.7 (male/
female 45/61). The age of the 28 patients that responded to the 
questionnaire ranged from 9 to 57 years (though parents/caretakers 
were present to give informed consent for the eight respondents that 
were aged <18 years). The age of the patients for whom a parent/
caretaker responded ranged from 1 to 17 years. The most common 
caretakers were parents (74, 92.5%)
Education levels of the patients were low with no patients com-
pleting secondary education or higher (Table 3). The education 
levels of the patient/caretakers that attended the clinic (i.e. those 
likely administering the ACT treatment to children) were not 
assessed.
The mean household size was 8.6 members and ranged between 1 
and 26 (median: 8, Q25–Q75: 5–10.5). The mean number of chil-
dren aged <5 years per household were 2.6 and ranged between 0 
and 13 (median: 2, Q25–Q75: 2–3) (Table 4). The main profession 
of heads of households was subsistence farming alone (46, 42.6%), 
and this occupation was named in combination with others for an 
additional 40 households (86, 79.6%).
Patient adherence
A total of six (5.6%) patients had one or more pills left at the time 
of the home visit on Day 3 when all pills should have been taken 
(Table 5). They were defined as certainly non-adherent. Thirty-
five (32.4%) patients were defined as probably non-adherent after 
describing an incomplete intake (including eight patients that took 
ASAQ pills on Day 3) and 67 (62.0%) patients were described as 
probably adherent after describing a complete and correct intake 
(Table 5). Merging the two non-adherent groups gave 41 (38.0%) 
non-adherent patients.
Table 2. Patient flow through study.
Patient flow through study Number of patients (N)
Proportion of centre 
questionnaires (%)
Centre questionnaires 274 100.0
RDT-positive and ACT prescription 150 54.7
ACT prescription and eligible 117 42.7
Lost to follow up* 9 3.3
Home questionnaires 108 39.4
Exit questionnaires 117
*Reasons for loss to follow up included; temporarily out of the village (6), wrong address 
(1), age was <1 year (1), household already visited. No patients were lost to follow-up due 
to admission to hospital.
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Table 3. Socio-demographic description of the study population (patients and caretakers).
Socio-demographic factor N % Socio-demographic factor N %
Age groups (years) Origin
        ≤1 (infant) 13 12.0%         Resident 67 62.0%
        2–5 (young child) 47 43.5%         IDP 41 38.0%
        6–13 (adolescent) 23 21.3%         Total 108 100.0%
        ≥14 (adult) 25 23.2%
        Total 108 100.0% Sex
        Male 45 41.7%
Mean age (years) 10.5         Female 61 56.5%
Median age (years) 5         Not known 2 1.8%
Range (years) 1-57         Total 108 100.0% 
Caretaker relation to patient Highest education level of patient
        Patient 28 25.9%         Can’t read/write 46 42.6%
        Father/Mother 74 68.5%         Primary incomplete 47 43.5%
        Grandfather/Grandmother 5 4.6%         Primary complete 4 3.7%
        Brother/Sister 1 1.0%         Secondary incomplete 11 10.2%
        Total 108 100.0%         Secondary complete 0 0%
        Higher incomplete 0 0%
        Higher complete 0 0%
         Total 108 100.0%
However it should be noted that in order to analyse these data, 
assumptions had to be made for missing data, primarily an assump-
tion had to be made for 25 patients on Day 0 that ASAQ had been 
taken only once that day (at the clinic) and had been taken at the 
same time as the dose on Day 1 and Day 2 (which actually matched 
each other in all cases).
This adherence was calculated based on the number of pills taken, 
the number of times pills were taken per day and the number of days 
completed. However the timing of the daily dose and whether the 
medication was retained (not vomited or spat out) are also impor-
tant. Both could result in a reduction of anti-malarial activity dur-
ing the treatment phase and potential treatment failure. Using this 
stricter definition of adherence, 21 patients that had been defined as 
probably adherent became probably non-adherent (data not shown). 
Twelve (57.1%) of these patients did not take doses at the correct 
time of day, eight (38.1%) patients vomited or spat their pills and 
one (4.8%) patient vomited or spat their pills and also did not take 
doses at the correct time of day.
Reasons for incomplete, incorrect or correct intake
Reasons for 1) pills remaining or 2) a description of incorrect intake 
or 3) a description of correct intake were noted for each patient. 
However, 22 (62.9%) of the 35 probably non-adherent patients 
had missing data for reasons for incorrect intake and 19 of the 67 
(28.4%) probably adherent patients had missing data for reasons 
for correct intake.
This analysis only considered the individuals classified into the 
appropriate categories (non-strict adherence). The main reason 
for pills remaining (incomplete treatment intake) were forgetting 
to give/take the treatment and patient didn’t feel better/treatment 
wasn’t working + felt unwell (2, 33.3% respectively) (Table 6). 
Unfortunately the design of the questionnaire did not allow analysis 
of whether a replacement dose was taken.
The most common reasons for incorrect intake were that the patient 
forgot to take/caretaker forgot to give the pills, claimed the wrong 
instructions were given at the clinic or the patient was vomiting 
(3, 8.5% respectively) (Table 6).
Taken together the most common reason patients gave for incom-
plete and/or incorrect intake was that they were vomiting or felt 
unwell (10 patients (24.4%)).
The most common reasons for correct ACT intake was that the 
correct instructions were given at the clinic (32, 47.8%) and the 
patient/caretaker had been given the same medicine before and 
knew how to take it + Correct instructions were given at the clinic 
(13, 19.4%) (Table 6).
Page 6 of 16
F1000Research 2015, 4:51 Last updated: 13 APR 2015
Table 4. Socio-demographic description of the study households.
Demographic data Households
Number of household members N %
         1–4 members 29 26.9%
         5–8 members 32 29.6%
         9–12 members 34 31.5%
         >13 members 13 12.0%
         Total 108 100.0%
Mean household size (members) 8.6
Median household size (members) 8
Number of children <5 in households N %
         0 children 9 8.3%
         1 children 16 14.8%
         2 children 34 31.5%
         3 children 29 26.9%
         4 children 10 9.3%
         5 children 3 2.8%
         6 children 5 4.6%
         ≥10 children 2 1.8
         Total 97 100.0
Mean number of children <5 per household 2.6
Median number of children <5 per household 2
Profession of head of household N %
         Subsistence farmer 46 42.6%
         Subsistence farmer + Daily worker 8 7.4%
         Subsistence farmer + Other profession* 6 5.6%
         Subsistence farmer + Farmer for trading 5 4.6%
         Health worker 5 4.6%
         No work 5 4.6%
         Workman 4 3.7%
         Subsistence farmer + Hunter 4 3.7%
         Subsistence farmer + Teacher 3 2.8%
         Subsistence farmers + Other professions† 14 13.0%
         Other professions‡ 7 6.5%
         Missing 1 0.9%
         Total 108 100.0%
*Includes blacksmith (1), coalman (1), dressmaker (1), mason (1), sells fish oils (1), sells wood (1). 
†Includes health worker (2), student (2), no work (2), workman (2), trader (2), daily worker + other 
(1), daily worker + teacher (1), trader + other (1), farmer for trading + workman (1). ‡Includes 
guard (2), no work + other (1), daily worker + health worker (1), trader (1), farmer for trading + 
daily worker (1), farmer for trading + trader (1).
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Table 5. Adherence to currently used ACT treatment (ASAQ) for uncomplicated malaria.
Calculation of adherence Incomplete/incorrect intake described
Complete/correct 
intake described Total
No blister 21 34 55
Blister empty 14 33 47
Blister with pills 6 0 6
Total 41 67 108
Classification of adherence Number of patients (N) Proportion (%) 95% CI
Certain non-adherence 6 5.6% 1.24-9.88%
Probable non-adherence 35 32.4% 23.58-41.23%
Probable adherence 67 62.0% 52.88-71.99%
Total 108 100.0%
Adherence status Number of patients (N) Proportion (%) 95% CI
Non-adherent 41 38.0% 28.81-47.12%
Adherent 67 62.0% 52.88-71.99%
Total 108 100.0%
Assessment of possible risk factors
Univariate analyses of potential risk factors for non-adherence 
were explored (using the non-strict adherence classification). 
These included sex, weight classes (instead of age groups), educa-
tion level of the patient, knowledge that mosquito bites can cause 
malaria, knowledge that LLINs prevent malaria and presence of 
observed LLINs in the household. Significant association with 
adherence was observed only for sex (χ2 = 8.1, P= 0.017, Table 7). 
Women were more likely to adhere to ACT treatment. Sex remained 
significantly associated when considering strict adherence 
(χ2 = 8.9, P= 0.031, Table 8) and when merging certain and proba-
ble non-adherence into a single ‘non-adherence’ category (χ2 = 8.1, 
P= 0.004 for non-strict adherence only, Table 9, Table 10).
These risk factors were analysed in a logistic regression where the 
sex of the patient only was significantly associated with adherence 
(Table 11).
Exit-questionnaires
Socio-demographic description of the exit group
Patients or caretakers/parents in the exit population had broadly 
the same socio-demographic and clinical characteristics as those 
who were interviewed at home for the adherence study (i.e. sex of 
patient, caretaker relation to patient, education level of the patient).
The weight categories showed significantly higher infants and adults 
in the exit group (χ2=9.34, P=0.026 for age group and χ2=9.16, 
P=0.05 for weight class).
Comprehension of ACT treatment schedule by exit group
In the exit-questionnaires group, a high number of the malaria 
patients or their respective caretakers (114, 97.4%) knew the name 
of the disease or could name the correct signs/symptoms of malaria 
(Table 12). Similarly a high number (101, 86.3%) were able to 
identify the ACT pills among all the given pills and to indicate to 
the interviewer that they were an anti-malarial. Similarly, a high 
proportion of patients/caretakers (116, 99.2%) correctly said they 
would take the next dose the following day (though only six, 5.1% 
mentioned the time), correctly said they would take the next dose 
the day after (116 (99.2%), though only five, 4.3% mentioned the 
time), claimed that they would take all ACT pills and would there-
fore not have a balance at the end of the ACT course (117, 100.0%), 
claimed they would continue taking ACT treatment the follow-
ing day even if their condition improved (115, 98.3%) and stated 
they would return to the clinic if their condition did not improve 
after 3 days (114, 97.4%) (Table 12). This indicated a high level of 
understanding of ACT administration. However, only 87 (74.4%) 
patients/caretakers could repeat the number of times per day pills 
should be taken and 76 (65.0%) could repeat the number of pills to 
take (Table 12).
However, the Outpatient Department (OPD)/pharmacy performance 
was not consistent. Despite 107 (91.5%) of the patients/caretakers 
being asked if they had understood the instructions given to them, 
only 41 (35.0%) had been asked to repeat these instructions and 
only 90 (76.9%) were given additional information, mainly advised 
to return to the clinic to get a dose if they vomited or spat up a dose 
(51, 43.6%) and informed that ACT can cause fatigue but they must 
continue the treatment (16, 13.7%). Also a high but not optimal 
number of patients (101, 86.3%) had taken a dose of ACT at the 
clinic under supervision.
Discussion
This study found that six (5.6%) patients were certainly non- 
adherent; therefore approximately one out of 18 patients did not 
complete the course of ACT treatment within the timeframe of 
3 days. From the verbal account of the patients or caretakers, 
another 35 (32.4%) patients took the treatment in a different way 
to how it was prescribed (probable non-adherence). Therefore, only 
67 (62.0%) patients could be considered probably adherent.
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Table 6. Reasons given by patients for incomplete, incorrect and correct ACT intake.
Reason for ACT intake Number of patients (N) Proportion (%)
Reasons given for incomplete intake (pills remaining)
Forgot to give/take 2 33.3
Patient didn’t feel better/Treatment wasn’t working + Felt unwell 2 33.3
Felt unwell 1 16.7
Patient didn’t feel better/Treatment wasn’t working 1 16.7
Total 6 100.0
Reasons given for incorrect intake
Forgot to give/take 3 8.5%
Claims wrong instructions/dosage were given in the clinic 3 8.5%
Patient was vomiting 3 8.5%
Felt sick/unwell straight after taking the pills 1 2.9%
Thought patient would cure faster 1 2.9%
Thought patient would cure faster + Felt sick/unwell straight after 
taking the pills 1 2.9%
Thought patient would cure faster + Claims that wrong instructions/
dosage were given in the clinic + Felt sick/unwell straight after 
taking the pills
1 2.9%
Missing data 22 62.9%
Total 35 100.0
Reasons given for correct intake
Correct instructions given at the clinic 32 47.8%
Given the same medicine before and knows how to take it + Correct 
instructions given at the clinic 13 19.4
Wanted to heal 1 1.5%
Child strong enough to take the medicine 1 1.5%
Given the same medicine before and knows how to take it + Was 
helped by the community health volunteer (ASC) 1 1.5%
Missing data 19 28.3%
Total 67 100.0
Table 7. Univariate analysis of sex and non-strict adherence (all 
categories), Pearson χ2 = 8.10, P = 0.017 (Fishers exact P = 0.013).
Sex Total
Non-strict adherence Male Female
Certain non-adherence 3 (6.6%) 2 (3.2%) 5 (4.7%)
Probable non-adherence 21 (46.7%) 14 (23.0%) 35 (33.0%)
Probable adherence 21 (46.7%) 45 (73.8%) 66 (62.3%)
Total 45 (100.0%) 61 (100.0%) 106 (100.0%)
Table 8. Univariate analysis of sex and strict adherence (all categories), Pearson χ2 = 8.91, 
P = 0.031 (Fishers exact P = 0.026).
Sex Total
Strict adherence Male Female
Certain non-adherence 3 (6.6%) 2 (3.3%) 5 (4.7%)
Probable non-adherence (incomplete intake) 21 (46.7%) 14 (23.0%) 35 (33.0%)
Probable non-adherence (incorrect intake) 5 (11.1%) 16 (26.2%) 21 (19.8%)
Probable adherence 16 (35.6%) 29 (47.5%) 45 (42.5%)
Total 45 (100.0%) 61 (100.0%) 106 (100.0%)
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Table 10. Univariate analysis of sex and strict adherence (all 
categories), Pearson χ2 = 1.5, P = 0.217 (Fishers exact P = 0.239).
Sex Total
Strict adherence Male Female
Non-adherence 29 (64.4%) 32 (52.5%) 61 (57.5%)
Adherence 16 (35.6%) 29 (47.5%) 45 (42.5%)
Total 45 (100.0%) 61 (100.0%) 106 (100.0%)
Table 9. Univariate analysis of sex and non-strict adherence (all 
categories), Pearson χ2 = 8.10, P = 0.004 (Fishers exact P = 0.008).
Sex Total
Non-strict adherence Male Female
Non-adherence 24 (53.3%) 16 (26.2%) 40 (37.7%)
Adherence 21 (46.7%) 45 (73.8%) 66 (62.3%)
Total 45 (100.0%) 61 (100.0%) 106 (100.0%)
This did not take into account the patients that vomited or spat their 
pills or took the pills at the incorrect time of day. In that case the 
adherence dropped to 46 (42.6%). The effect of a decrease in anti-
malarial activity that would follow vomiting/spitting or failure to 
take a timely dose is not clear but it is thought that this risks a period 
of monotherapy to the partner drug in the ACT combination. Advice 
about timing of ACT dosages is not clear but it is thought that a 
3-hour margin either side of the expected timing is acceptable12.
The most common reason patients mentioned for incomplete (67%) 
and incorrect (20%) intake was that they were vomiting or felt 
unwell. This appears to indicate that there was a poor understanding 
of the seriousness of the disease and the importance of finishing the 
treatment or that the side effects of ASAQ treatment were signifi-
cant enough to over-ride the pharmacy instructions, unlike previous 
MSF studies using Coartem®8.
More than a third of the study population claimed not to know the 
cause of malaria nor how to prevent malaria during home visits, but 
this was not significantly associated with non-adherence to ACT. 
Only sex of the patient was associated with adherence (males were 
significantly less likely to adhere to ASAQ). As the side effects 
were unlikely to affect males more than females, this may demon-
strate an indifference to malaria in the male population, a common 
disease seen regularly in Shamwana. Similarly in Ethiopia, a study 
of factors associated with non-use of bed nets found that malaria 
was not perceived by the population to be a problem despite high 
prevalence of the disease13.
When assessing the main reason for correct ACT intake, 45 (66.2%) 
patients claimed they were given the correct instructions at the 
OPD/pharmacy. When assessing the exit-questionnaires the 
quality of ACT prescriptions and the related instructions given 
at the OPD/pharmacy were less clear: 86.3% of the patients in 
the exit-questionnaires group were able to identify ACT as the 
anti-malarial treatment given to them amongst other concomitant 
treatments and 99.2% could correctly repeat the number of days 
Table 11. Multivariate regresssion of potential risk factors to ACT non-adherence.
Risk factors Non-adherent (n=40) % OR 95% CI P value
Patient sex
     Male (n=45) 24 53.3%
     Female (n=61) 16 26.2% 2.86 1.21-6.76 0.017
Patient weight
     Infant (n=7) 2 28.6%
     Young child (n=65) 26 40.0% 1.16 0.19-7.23 0.875
     Adolescent (n=17) 7 41.2% 0.82 0.11-6.12 0.847
     Adult (n=19) 5 26.3% 1.88 0.28-13.88 0.537
Education level
     Illiterate (n=46) 21 45.7%
     Any education (n=62) 20 32.3% 1.80 0.74-4.39 0.197
Malaria caused by mosquito bites
     Not mentioned (n=42) 20 47.6%
     Mentioned (n=66) 21 31.8% 1.98 0.64-6.19 0.238
Bednet prevents malaria
     Not mentioned (n=36) 15 41.6%
     Mentioned (n=72) 26 36.1% 0.85 0.25-2.92 0.795
Bednet observed
     No (n=47) 20 42.6%
     Yes (n=61) 21 34.4% 1.69 0.70-4.09 0.248
Page 10 of 16
F1000Research 2015, 4:51 Last updated: 13 APR 2015
Table 12. ACT treatment education and understanding in the exit group.
ACT treatment education and understanding No. patients/
caretakers (N)
Proportion patients/ 
caretakers (%)
Patient/caretaker understanding N=117
Understanding of malaria
         Able to name malaria 60 51.3%
         Able to describe symptoms only 54 46.2%
         Unable to describe disease or symptoms 3 2.5%
Recognition of ACT
         Can identify ACT 101 86.3%
         Can identify ACT with other drugs 10 8.6%
         Identifies other drugs only 4 3.4%
         Doesn’t know 2 1.7%
Taken ACT previously
         0 times 21 18.0%
         1-2 times 31 26.5%
         3-4 times 33 28.2%
         >5 times 31 26.5%
         Missing data 1 0.8%
Understanding of ACT schedule
         Repeated instructions correctly-Days 116 99.2%
         Repeated instructions correctly-Times 87 74.4%
         Repeated instructions correctly-Pills 76 65.0%
1st ACT dose observed in pharmacy 101 86.3%
Continuation of ACT treatment on Day 1 if condition improves
         No 2 1.7%
         Yes 115 98.3%
Action if no improvement after 3 days
         Return to hospital 114 97.4%
         Other 1 0.9%
         Missing data 2 1.7%
Health centre role
Patient was asked if s/he understood 107 91.5%
Patient was asked to repeat instructions 41 35.0%
Patient was given additional information (multiple responses possible):
         To return to clinic if pill vomited/spat 59 50.4%
         May cause fatigue but must continue 19 16.2%
         Complete the course 2 1.7%
         Take at the same time each day 2 1.7%
         Sleep under a bednet 2 1.7%
         Eat 1 0.9%
         No additional instructions 32 27.4%
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This study has shown that ACT adherence in this setting is inad-
equate and may have contributed to the increase in malaria cases (if 
recrudescence was a major cause). It should be noted however that 
there is no recommended target for adherence levels. Artemisinin 
is the best drug available to treat malaria and currently there are 
no real alternatives. Artemisinin resistance has likely arisen in 
Cambodia due to the use of artemisinin monotherapy19. Combina-
tion treatment with ACT when taken correctly reduces, but does 
not completely eliminate, the chance of resistant strains develop-
ing. Poor adherence could potentially expose greater numbers of 
parasites to the more slowly-eliminated partner drug in ACTs, 
increasing the risk of resistance to the partner drug20. Once resist-
ance has developed to the partner drug the ACT treatment would 
effectively become artemisinin monotherapy and hence render 
artemisinin vulnerable to resistance.
The effectiveness of ACT relies on both the efficacy of the drug 
components and on correct compliance. Adherence to ACT should 
not be taken for granted. At the community level, health communi-
cation campaigns that improve malaria knowledge and help them 
understand the importance of prevention and correct treatment 
should be carried out. At the clinic level, first ACT dose should 
always be observed at the pharmacy/OPD clinic and complete and 
clear patient instructions, including the importance of completing 
a course of ACT treatment and what to do if a dose is vomited or 
spat, should be given. The need to complete three sequential days 
of malaria treatment even if patients feel unwell or improve should 
be emphasised at both the community and clinic level.
Consent
Written informed consent was obtained from the patient/parent/
caretaker for the home questionnaires.
Verbal informed consent was obtained from the patient/parent/
caretaker for the exit questionnaires.
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that ACT should be taken. However, only 74.4% could repeat the 
number of times per day pills should be taken and 65.0% could 
repeat the number of pills to take.
Unfortunately the education level of the patients only was assessed, 
and not that of the caretakers. Therefore, any link between educa-
tion level and adherence to antimalarials, which have been shown 
previously to be associated, could not be deduced5,7. Knowledge that 
mosquito bites cause malaria did not show a statistically significant 
association with ACT adherence unlike findings of an ACT adher-
ence study in Bo, Sierra Leone8. No association was seen between 
adherence and age despite some observations in MSF projects that 
adherence is poor amongst adolescents.
Three ACT adherence studies carried out in MSF malaria projects 
had similar findings; certain non-adherence was 22.9% and prob-
able non-adherence 28.8% in a rural area of Sierra Leone, 18% and 
29% in a remote area in South Sudan and 21% and 39% respec-
tively in a refugee settlement in Zambia respectively6–8. These study 
settings had similar characteristics to Shamwana, such as a remote 
rural study area, low education level, treatment intake over 3 days, 
and treatment already implemented for a certain amount of time. 
Furthermore, our results are in line with a study carried out in two 
districts in Western Kenya that found a certain non-adherence of 
31.7% and probable non-adherence of 4.2%14 and another study 
in rural Sri Lanka using post-treatment interviews where 26% of 
patients self-reported defaulting. The main reasons given for not 
taking the entire regimen were side effects and disappearance of 
symptoms15.
However, studies in Uganda and Ghana showed certain non-adherence 
to be as low as 7% and probable non-adherence to be 3%7,16. In 
Tanzania, non-adherence was as low as 25%17. These higher adher-
ences might be explained by the fact that adherence assessments 
were carried out after the successful introduction of a new malaria 
treatment. The introduction of a new, efficient treatment is always 
accompanied by special training for health workers, which is linked 
with greater motivation, and giving a more detailed verbal explana-
tion to patients.
A recent systematic review found 37 studies that measured ACT 
adherence18. However all had varying definitions of adherence 
and used different study designs and methods to measure adher-
ence. Standardised methodologies for both self-report and bioassay 
measurements would improve the evidence base on ACT adherence 
and effectiveness.
Two different methods were used to measure adherence in patients: 
the pill count (observation of the blister pack) and a systematic 
questionnaire. Both assessment methods have their limitations: the 
pill count is a more objective measurement but gives incomplete 
information; the patient’s account is subjective and not verifiable 
but provides more information. By classifying patients as either 
certainly or probably non-adherent, the study accounted for the 
limitations of both methodologies.
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The authors should be congratulated for conducting this study in difficult circumstances. Given its very
large experience, MSF must be encouraged to contribute more to the fight against malaria, with this type
of operational research.
I have several comments and suggestions with regards to this study:
The authors wanted to investigate the reasons behind the rise in the number of malaria cases seen in their
programs in DRC and set out to determine whether it may be caused by poor observance to the
treatment.
In 2013 the clinic staff in Shamwana identified patients returning to the clinic with severe malaria after
having been prescribed a course of ACT (artesunate-amodiaquine). It would be very useful to know more
about these patients: where they from all age groups and both genders? What was the median time to the
recurrent episode? How far from the clinic did they come from? What was the mean duration of fever
before presentation? More generally it is important to have more details of the increasing number of cases
see in the clinic between 2009 and 2013: age and gender distributions as well as the number of
severe/uncomplicated cases.
There are several other potential reasons for the increase in cases: a larger population in the catchment
area (or population movements), climatic changes, poor quality medicine, antimalarial resistance. Poor
treatment observance is unlikely to be the only reason. The results of this study do not suggest that poor
observance is a major problem, specially because the definition of probably non-adherence is too strict:
taking the pills at a different time each day will not affect effectiveness. An interesting finding of the exit
questionnaire is that few patients were given important additional information (Table 12). This suggests
that the providers could probably improve the quality of the prescription. A useful indicator is the time
taken by the prescribers to explain to the patients how to take the medicines.
Finding out the real contribution of poor observance is not too complicated. A dry blood spot (DBS)
collected on all patients presenting with a positive RDT will be sufficient. One needs to know (from the
clinic records) if and when the patient was treated last time. The DBS can be used to measure the
concentration of amodiaquine in the blood as well as finding parasite DNA. Depending on the type of RDT
used, there is a possibility of false positive in the days/weeks after a treatment with ACT because of the
persisting HRP2 in the circulation. The DBS can be stored at room temperature and analyzed later. It may
identify that in fact the problem of increasing cases is mostly due to the emergence of resistance to
amodiaquine. In 2006 Swarthout and colleagues found a failure rate with ASAQ of 6.7% (5/74; 95% CI:
2.2-15.1) although in 2008-2009 another study (also from MSF) provided reassurance about the efficacy
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amodiaquine. In 2006 Swarthout and colleagues found a failure rate with ASAQ of 6.7% (5/74; 95% CI:
2.2-15.1) although in 2008-2009 another study (also from MSF) provided reassurance about the efficacy
of ASAQ (cure rate 98.3 (94.1-99.8) by day 42.
One suggestion to improve the impact of the intervention (LLIN and ACT) is to ensure that the diagnostic
(RDT) and treatment (ACT) is given as soon as possible after the beginning of fever (<48h). This is
because in order to prevent transmission, patients must be treated before the emergence of mature
gametocytes in the circulation. The addition of the low single dose primaquine (as recommended by
WHO) will help reducing transmission.
In conclusion, this is a useful paper, but some more epidemiological details about the case-load and
some simple investigations would help understanding the factors behind the increasing number of malaria
cases seen in MSF clinics. Setting up malaria posts in the villages, where people can go early in the
course of their fevers would help maximizing the impact on transmission.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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 Anne Moore
Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
This is an interesting paper from MSF epidemiologists that aims to determine some of the reasons for
significant increases in malaria cases in DRC. It is imperative to prevent the emergence of anti-malarial
drug resistance and patient adherence and compliance is critical to this issue. The data presented here
provides evidence of what is happening in the field and touches on patients’ attitudes and knowledge in
this area. The authors focus on patient compliance and statistically examine socio-demographic and other
factors for non-adherence to the prescribed time schedule and dosage. A key finding is the low rate of
adherence, which has significant impact on drug-based treatment of malaria. Non-adherence due to
vomiting or feeling unwell in a proportion of individuals is an important finding for the drug formulation
community; how can this be overcome by changing the formulation or possibly the route,  in the future? 
Timing was also highlighted as an obstacle to correct drug administration; again this is an obstacle that
should be tackled both by drug developers, practitioners in the field and those interested in health literacy.
The authors should consider minor revisions to their paper to discuss these issues in more depth. For
example, based on their data, what are the next critical steps that should be focused on; from both a
practice, and more long-term, drug design perspective? How can we succeed in patient education
relating to the importance of adherence and designing and implementing a system that results in better
patient adherence? Given that the authors found that gender is a significant factor; can the authors
suggest how this finding should be used to develop strategies to improve patient compliance? Finally, the
authors discuss the problems of trying to compare across studies due to different study designs and
methods. From a methodology perspective, therefore, it would be useful if the authors included the full
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methods. From a methodology perspective, therefore, it would be useful if the authors included the full
questionnaires used in this study as an appendix, with the objective of replication of the study in other
areas.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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